Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Total Liabilities (2020 - 2025)

Goldenwell Biotech filings provide 6 years of Total Liabilities readings, the most recent being $315233.0 for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 58.67% to $315233.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $315233.0, a 58.67% increase, with the full-year FY2024 number at $271433.0, up 88.71% from a year prior.
  • Total Liabilities hit $315233.0 in Q3 2025 for Goldenwell Biotech, down from $338133.0 in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $338133.0 in Q2 2025 to a low of $29126.0 in Q3 2022.
  • Median Total Liabilities over the past 5 years was $145222.0 (2024), compared with a mean of $144873.7.
  • Biggest five-year swings in Total Liabilities: tumbled 81.16% in 2022 and later skyrocketed 282.36% in 2024.
  • Goldenwell Biotech's Total Liabilities stood at $159266.0 in 2021, then tumbled by 70.63% to $46782.0 in 2022, then skyrocketed by 207.46% to $143837.0 in 2023, then surged by 88.71% to $271433.0 in 2024, then rose by 16.14% to $315233.0 in 2025.
  • The last three reported values for Total Liabilities were $315233.0 (Q3 2025), $338133.0 (Q2 2025), and $273533.0 (Q1 2025) per Business Quant data.